Of the 122 patients receiving grazoprevir and elbasvir , six were excluded from the primary efficacy analysis for non-virological reasons ( death , lost-to-follow-up [ n = 2 ] , non-compliance , patient withdrawal , and withdrawal by physician for violent behaviour ) .